Document is current
Any future updates will be listed below
-
Authors
Carty, J. R. E.
Devarakonda, K. https://orcid.org/0000-0002-4374-4670
O’Connor, R. M.
Krek, A.
Espinoza, D.
Jimenez-Gonzalez, M. https://orcid.org/0000-0002-7678-9058
Alvarsson, A.
Hampton, R. F. https://orcid.org/0000-0003-3285-6957
Li, R. https://orcid.org/0000-0002-2605-634X
Qiu, Y.
Petri, S.
Shtekler, A.
Rajbhandari, A. https://orcid.org/0000-0002-5596-8735
Conner, K.
Bayne, M.
Garibay, D.
Martin, J.
Lehmann, V.
Wang, L.
Beaumont, K. https://orcid.org/0000-0003-3075-9977
Kurland, I.
Yuan, G. C. https://orcid.org/0000-0002-2283-4714
Kenny, P. J.
Stanley, S. A. https://orcid.org/0000-0002-0253-2663
- License Information
-
More Information
Article History
Received: 10 May 2023
Accepted: 16 July 2025
First Online: 3 September 2025
Competing interests
: S.A.S. is a named inventor of patents granted by the United States Patent and Trademark Office: ‘Compositions and Methods to Modulate Cell Activity’ (US 9,399,063 and US 10,064,941) and ‘Ferritin nanoparticle compositions and methods to modulate cell activity’ (US 10,786,570). P.J.K. is a co-founder of Eolas Therapeutics, which is developing novel treatments for substance use disorders. P.J.K. is a consultant for EpiVario.
